etrials, a developer of “eclinical” technology for use in clinical trials, has paid $1.75 million to settle a patent dispute.

Datasci alleged that etrials had infringed on technology used in collection and validation of clinical trial data. etrials (Nasdaq: ETWC) agreed to pay Datasci the $1.75 million as an upfront license fee for the disputed technology.

“We are very pleased to have reached an amicable settlement with regard to this matter, allowing us to move forward with enhancements to our product portfolio,” said Chip Jennings, president and CEO. “We believe this agreement to be in the best interest of the company and its shareholders. The settlement limits any future exposure and allows us to focus all of our attention on improving etrials’ core operations and expanding our market share within the rapidly growing market for eClinical technologies and services.”